In patients with prior ischemic stroke, are angiotensin‑receptor blockers (ARBs) equivalent to angiotensin‑converting‑enzyme inhibitors (ACE inhibitors) for antihypertensive therapy in secondary stroke prevention?

ARBs and ACEIs Show Equivalent Efficacy for Secondary Stroke Prevention

Both ARBs and ACEIs are equivalent options for antihypertensive therapy in secondary stroke prevention, as the primary benefit derives from blood pressure reduction itself rather than the specific drug class chosen. 1

Evidence from Guidelines

The American Heart Association/American Stroke Association guidelines establish that:

• Blood pressure reduction is the critical intervention for preventing recurrent stroke in patients beyond 24 hours after ischemic stroke or TIA, with benefit extending to both hypertensive and normotensive patients (Class I, Level A evidence). 1

• No direct superiority has been established between ACEIs and ARBs specifically for secondary stroke prevention. The 2011 guidelines note that "calcium channel blockers and angiotensin receptor blockers were not evaluated in any of the included trials" that demonstrated stroke reduction, limiting direct comparisons. 1

• Diuretics combined with ACEIs showed significant reductions in recurrent stroke in landmark trials (PROGRESS study), but ACEIs alone did not demonstrate significant benefit, suggesting combination therapy may be optimal. 1

Research Evidence on Comparative Effectiveness

Meta-Analysis Findings

A 2012 meta-analysis of 8 randomized controlled trials with 29,667 participants found that renin-angiotensin system modulators (ACEIs or ARBs combined) modestly reduce vascular risk in persons with prior stroke:

• Relative risk reduction of 9% for major vascular events (RR 0.91, NNT=71) 2
• Relative risk reduction of 7% for recurrent stroke (RR 0.93, NNT=143) 2
• No obvious heterogeneity between different study characteristics in subgroup analyses, suggesting similar effects across drug types 2

Recent Expert Consensus (2024)

The Egyptian Cardiology Expert Consensus provides nuanced recommendations:

• ACEIs should be considered first choice for secondary prevention of stroke based on available evidence 3
• ARBs are indicated as alternatives in patients who cannot tolerate ACEIs (primarily due to cough) 3
• However, this recommendation acknowledges that ACEIs and ARBs show equivalent efficacy for primary prevention of stroke, and the secondary prevention preference is based on broader cardiovascular outcomes rather than stroke-specific data 3

Clinical Algorithm for Drug Selection

For patients with prior ischemic stroke requiring antihypertensive therapy:

1. First-line: ACEI (preferably combined with a thiazide diuretic) based on PROGRESS trial evidence showing significant stroke reduction with this combination 1, 3

2. Alternative: ARB if ACEI not tolerated (e.g., due to cough, which occurs in approximately 5-10% of patients) 3

3. Special populations:

   • Black patients: Consider thiazide-type diuretics or calcium channel blockers as first-line or in combination 4
   • Patients with diabetes: ACEI preferred for renal protection and cardiovascular risk reduction 3
   • Patients with heart failure or reduced ejection fraction: ARNI (angiotensin receptor/neprilysin inhibitor) first choice, ACEI second choice 3
   • Patients with compelling cardiac indications (post-MI, coronary disease): ACEI within 24 hours of STEMI 3

4. Target blood pressure reduction: Approximately 10/5 mmHg reduction associated with benefit, targeting <120/80 mmHg 1

Important Caveats

The magnitude of benefit is modest (NNT=143 for preventing one recurrent stroke), emphasizing that blood pressure control through any effective agent is more important than the specific drug class selected. 2

Adherence to guideline-based prescribing remains suboptimal. A 10-year review from the Florida Stroke Registry found BP-guideline adherence rates of only 48-74%, well below the 80% quality standard, with particular disparities among Black patients and those with diabetes. 4

Combination therapy appears superior to monotherapy based on the PROGRESS trial showing benefit with perindopril plus indapamide but not perindopril alone. 1

Avoid beta-blockers as first-line unless there is a compelling cardiac indication, as they did not show significant stroke reduction in secondary prevention trials. 1

The practical takeaway: Start with an ACEI (or ARB if ACEI not tolerated), preferably combined with a thiazide diuretic, and titrate to achieve adequate blood pressure control—the degree of BP reduction matters more than the specific agent chosen. 1, 2